Wellcome Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK.
Wellcome Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, UK.
J Inherit Metab Dis. 2020 Jan;43(1):36-50. doi: 10.1002/jimd.12104. Epub 2019 May 10.
Mitochondrial disease is hugely diverse with respect to associated clinical presentations and underlying genetic causes, with pathogenic variants in over 300 disease genes currently described. Approximately half of these have been discovered in the last decade due to the increasingly widespread application of next generation sequencing technologies, in particular unbiased, whole exome-and latterly, whole genome sequencing. These technologies allow more genetic data to be collected from patients with mitochondrial disorders, continually improving the diagnostic success rate in a clinical setting. Despite these significant advances, some patients still remain without a definitive genetic diagnosis. Large datasets containing many variants of unknown significance have become a major challenge with next generation sequencing strategies and these require significant functional validation to confirm pathogenicity. This interface between diagnostics and research is critical in continuing to expand the list of known pathogenic variants and concomitantly enhance our knowledge of mitochondrial biology. The increasing use of whole exome sequencing, whole genome sequencing and other "omics" techniques such as transcriptomics and proteomics will generate even more data and allow further interrogation and validation of genetic causes, including those outside of coding regions. This will improve diagnostic yields still further and emphasizes the integral role that functional assessment of variant causality plays in this process-the overarching focus of this review.
线粒体疾病在相关临床表现和潜在遗传原因方面存在巨大差异,目前已描述了超过 300 种疾病基因的致病性变异。由于下一代测序技术(特别是无偏见的全外显子组测序,后来是全基因组测序)的广泛应用,大约一半的变异是在过去十年中发现的。这些技术允许从线粒体疾病患者中收集更多的遗传数据,持续提高临床环境中的诊断成功率。尽管取得了这些重大进展,但仍有一些患者尚未明确诊断出遗传原因。含有大量未知意义变异的大型数据集已成为下一代测序策略的主要挑战,这些数据集需要进行大量的功能验证来确认致病性。诊断学和研究之间的这种接口对于不断扩展已知致病性变异的列表并同时增强我们对线粒体生物学的认识至关重要。全外显子组测序、全基因组测序和其他“组学”技术(如转录组学和蛋白质组学)的广泛应用将产生更多的数据,并允许进一步研究和验证遗传原因,包括编码区以外的原因。这将进一步提高诊断效果,并强调功能评估变异因果关系在这一过程中的重要作用——这是本综述的主要重点。